NVIV - InVivo Therapeutics Holdings Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 56.05M
Enterprise Value 3-5.39M
Trailing P/E N/A
Forward P/E 1-0.70
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.45
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 60.51

Trading Information

Stock Price History

Beta (3Y Monthly) 0.82
52-Week Change 3-67.15%
S&P500 52-Week Change 36.90%
52 Week High 32.7500
52 Week Low 30.6100
50-Day Moving Average 30.7757
200-Day Moving Average 31.2966

Share Statistics

Avg Vol (3 month) 375.28k
Avg Vol (10 day) 370.22k
Shares Outstanding 59.31M
Float 9.29M
% Held by Insiders 10.26%
% Held by Institutions 113.14%
Shares Short (Jun 28, 2019) 4112.41k
Short Ratio (Jun 28, 2019) 41.24
Short % of Float (Jun 28, 2019) 41.21%
Short % of Shares Outstanding (Jun 28, 2019) 41.21%
Shares Short (prior month May 31, 2019) 4221.46k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 225/1
Last Split Date 3Apr 17, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-44.25%
Return on Equity (ttm)-194.58%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -10.65M
Net Income Avi to Common (ttm)-21.27M
Diluted EPS (ttm)-3.0570
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)13.2M
Total Cash Per Share (mrq)1.42
Total Debt (mrq)1.48M
Total Debt/Equity (mrq)10.96
Current Ratio (mrq)6.86
Book Value Per Share (mrq)1.46

Cash Flow Statement

Operating Cash Flow (ttm)-11.98M
Levered Free Cash Flow (ttm)-7.63M